RxDoctor Payments Data

Aubreigh Godleski, PA

Physician Assistant · Phillipsburg, NJNPI 1346719622

Payments from drug & device makers

$2,368in general payments, 2019–2025

Across 89 payments — averaging $26.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$642
  • Neurocrine Biosciences, Inc.$320
  • Teva Pharmaceuticals USA, Inc.$144
  • Otsuka America Pharmaceutical, Inc.$125
  • Rigel Pharmaceuticals, Inc.$125
  • Harmony Biosciences LLC$119
  • plus $893 from 19 others

What the payments were for

  • Food & beverage$2,26896%
  • Education$1004%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,368 in reported general payments places this provider in the 85th percentile of 2,726 physician assistant providers in New Jersey.

See all physician assistant providers in New Jersey

Medicare billing

Part B allowed, 2024
$65,715
Medicare patients
119
Services billed
877

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate11$93,653
Lurasidone Hcl65$11,993
Bupropion XlBupropion Hcl146$7,134
VyvanseLisdexamfetamine Dimesylate17$6,384
Desvenlafaxine Succinate ErDesvenlafaxine Succinate50$3,682
Duloxetine Hcl125$3,604
Vilazodone Hcl43$2,743
Aripiprazole119$2,534
Buspirone Hcl126$1,818
Venlafaxine Hcl ErVenlafaxine Hcl62$1,795
Escitalopram Oxalate154$1,625
Trazodone Hcl131$1,505
Alprazolam229$1,418
Clonazepam131$1,399
Paliperidone ErPaliperidone15$1,318

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$320$93,65311 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$101$6,38417 claims
Lilly USA, LLCOlanzapine$50$50734 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,726 physician assistant providers in New Jersey.

Other physician assistant in Phillipsburg

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →